Pfizer and Lilly reach all three trials on the painkiller tanezumab

today, Pfizer and Lilly jointly announced that they had reached the end of all three trials in the three-stagetrialfor pain management of osteoarthritis (OA)about Tanezumab
Tanezumab is a human-derived monoclonal antibodydrug(optional binding and inhibition of neurogrowth factors (NGF)NGF is thought to mediate chronic pain in a variety of diseases, while injury, inflammation and chronic pain usually lead to elevated levels of NGF in the bodyBy selectively inhibiting NGF, tanezumab may help block the flow of pain signals from muscles, skin and organs into the spinal cord and brainTanezumab has a new mechanism of action, unlike opioids and other analgesics, including nonsteroidal anti-inflammatory drugs (NSAIDs)Tanezumab's research now focuses on three types of pain management: OA, chronic lumbar, and bone metastasis cancer painthe three-year study, which was reported for 16 weeks, was injected with a drug or placebo every eight weeks, for a total of two injections698 patients were randomly divided into 3 groups of 1:1:1, one group received 2 2.5 mg tanezumab, one group received 2.5 mg, one 5 mg tanezumab, and one group received 2 placebosThe trial ended with a 16-week-old WOMAC (Western o
ntario and McMaster Universities Osteoarthritis Index pain scale, a WOMAC body machine energy meter, and a comprehensive assessment of patient OA status compared to the baselinetest results showed that tanezumab reached the end of all three trials and showed excellent toleranceOnly 1% of patients terminated the trial because of side effects Less than 1.5% of patients in the treatment group experienced rapid progressoon of OA